Table 4 Relationships between the prognostic (+/- relapses) and the mRNA levels of the 47 selected genes in 100 ERα-positive breast tumors
From: Identification of a three-gene expression signature of poor-prognosis breast carcinoma
GENES | Tumors without relapses (n = 63) | Tumors with relapses (n = 37) | P a | ROC-AUCb |
|---|---|---|---|---|
BRCA2 | 4.6 (1.0–12.4) c | 7.1 (1.9–18.8) | 0.0011 | 0.696 (0.59–0.80) d |
DNMT3B | 3.0 (1.0–13.6) | 4.6 (1.2–17.4) | 0.0015 | 0.690 (0.58–0.80) |
CCNE1 | 6.2 (1.0–36.9) | 8.9 (3.1–82.5) | 0.0038 | 0.674 (0.57–0.78) |
HMMR/RHAMM | 18.9 (1.0–163.5) | 30.1 (3.8–186.5) | 0.0068 | 0.663 (0.55–0.77) |
MKI67 | 9.1 (1.0–49.8) | 14.4 (1.7–54.9) | 0.016 | 0.645 (0.53–0.75) |
TERT | 18.7 (1.0–121.9) | 22.1 (1.8–135.8) | 0.049 | 0.618 (0.50–0.73) |
TOP2A | 40.9 (1.0–306) | 55.6 (6.1–317) | NS | 0.605 (0.49–0.72) |
PLAU/UPA | 4.6 (1.0–36.4) | 5.8 (1.4–34.0) | NS | 0.588 (0.47–0.70) |
CGB | 4.2 (1.0–31.2) | 6.4 (1.4–32.8) | NS | 0.579 (0.46–0.70) |
ERBB2 | 14.0 (1.0–175) | 16.3 (4.2–179.8) | NS | 0.573 (0.46–0.69) |
BRCA1 | 11.9 (1.0–44.5) | 14.3 (1.8–62.5) | NS | 0.569 (0.45–0.69) |
CXCR4 | 6.5 (1.0–40.5) | 7.5 (1.5–71.5) | NS | 0.569 (0.45–0.68) |
PTTG1/Securin | 1.9 (1.0–26.9) | 1.9 (1.2–33.1) | NS | 0.566 (0.45–0.68) |
SRC | 2.6 (1.0–4.3) | 2.9 (1.4–10.2) | NS | 0.561 (0.45–0.67) |
p16/CDKN2A | 3.4 (1.0–107.4) | 4.4 (1.1–136.7) | NS | 0.560 (0.44–0.68) |
AREG | 89.3 (1.0–5667) | 110.1 (3.1–3301) | NS | 0.555 (0.44–0.67) |
SERPINE1/PAI1 | 3.8 (1.0–21.4) | 4.5 (1.3–21.8) | NS | 0.554 (0.44–0.67) |
ERBB3 | 2.6 (1.0–10.7) | 3.3 (1.2–13.4) | NS | 0.552 (0.44–0.67) |
SERPINB5/Maspin | 12.6 (1.0–321) | 16.4 (1.0–718) | NS | 0.551 (0.43–0.67) |
CDH1 | 11.3 (1.0–32.6) | 13.9 (1.5–33.3) | NS | 0.549 (0.43–0.67) |
p15/CDKN2B | 3.5 (1.0–16.2) | 4.2 (1.0–34.9) | NS | 0.548 (0.43–0.67) |
SPP1/Osteopontin | 43.3 (1.0–1403) | 56.8 (2.1–941) | NS | 0.548 (0.42–0.68) |
ETV4/PEA3/E1AF | 5.1 (1.0–49.3) | 6.9 (1.8–62.0) | NS | 0.545 (0.43–0.66) |
CP/Ceruloplasmin | 33.5 (1.0–9815) | 81.5 (1.0–33943) | NS | 0.545 (0.42–0.67) |
SERPINB2/PAI2 | 13.0 (1.0–498) | 15.3 (1.0–1652) | NS | 0.535 (0.42–0.65) |
TIAM1 | 13.6 (1.0–55.9) | 13.3 (3.9–83.2) | NS | 0.526 (0.41–0.64) |
RB1 | 4.2 (1.0–7.4) | 4.3 (1.5–7.7) | NS | 0.520 (0.40–0.64) |
AR | 54.2 (1.0–219) | 64.8 (1.0–211) | NS | 0.518 (0.40–0.64) |
HAS2 | 6.5 (1.0–40.8) | 6.4 (1.4–31.9) | NS | 0.516 (0.40–0.63) |
TFF1/pS2 | 1772 (1.0–138 545) | 1783 (3–55 878) | NS | 0.509 (0.39–0.62) |
ESR2/ERβ | 28.2 (1.0–368) | 25.3 (1.4–219) | NS | 0.500 (0.38–0.62) |
ERBB4 | 141 (1.0–1489) | 143 (2.1–1062) | NS | 0.483 (0.37–0.60) |
KRT19 | 14.4 (1.6–99.1) | 10.8 (1.0–57.1) | NS | 0.482 (0.36–0.60) |
ESR1/ERα | 25.5 (1.0–508) | 21.7 (1.2–498) | NS | 0.479 (0.36–0.60) |
CXCL12 | 12.1 (1.3–36.1) | 9.6 (1.0–30.5) | NS | 0.464 (0.35–0.58) |
MYC | 8.1 (1.0–35.5) | 7.5 (1.0–51.2) | NS | 0.464 (0.35–0.58) |
EGFR/ERBB1 | 8.3 (1.2–108) | 6.2 (1.0–66.8) | NS | 0.462 (0.34–0.58) |
ARHC/RhoC | 6.9 (1.0–192) | 6.3 (1.0–17.2) | NS | 0.458 (0.34–0.58) |
p14/ARF | 4.9 (1.4–68.1) | 4.4 (1.0–61.2) | NS | 0.457 (0.34–0.57) |
XLKD1/LYVE-1 | 4.5 (1.4–10.9) | 3.7 (1.0–10.7) | NS | 0.448 (0.33–0.57) |
CD44 | 3.1 (1.2–9.6) | 2.7 (1.0–8.4) | NS | 0.440 (0.32–0.56) |
CGA | 17.6 (1.0–16 552) | 6.4 (1.0–5 836) | NS | 0.425 (0.31–0.54) |
CAV1 | 7.4 (1.1–30.7) | 5.6 (1.0–26.6) | NS | 0.422 (0.31–0.54) |
BCL2 | 4.9 (1.2–13.3) | 3.2 (1.0–11.8) | NS | 0.415 (0.30–0.53) |
PGR/PR | 277 (1.0–8 034) | 97 (1.0–4 551) | NS | 0.412 (0.29–0.53) |
PTGS2/COX2 | 4.6 (1.0–154) | 3.0 (1.0–14.8) | NS | 0.397 (0.28–0.51) |
CCND1 | 6.3 (1.2–45.3) | 4.0 (1.0–21.3) | 0.042 | 0.378 (0.26–0.50) |